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Background: Hyperlipidemia is thought to be a major risk factor for the progression of renal diseases in diabetes.
Recent studies have shown that lipid profiles are commonly abnormal early on type 2 diabetes mellitus (T2DM)
with diabetic nephropathy. However, the early effects of triglyceride and cholesterol abnormalities on renal injury in
type 1 diabetes mellitus (T1DM) are not fully understood and require reliable animal models for exploration of the
underlying mechanisms. Hamster models are important tools for studying lipid metabolism because of their
similarity to humans in terms of lipid utilization and high susceptibility to dietary cholesterol and fat.
Methods: Twenty-four male Golden Syrian hamsters (100–110 g) were rendered diabetes by intraperitoneal
injections of streptozotocin (STZ) on consecutive 3 days at dose of 30 mg/kg, Ten days after STZ injections,
hamsters with a plasma Glu concentration more than 12 mmol/L were selected as insulin deficient ones and
divided into four groups (D-C, D-HF, D-HC, and D-HFHC), and fed with commercially available standard rodent
chow, high-fat diet, high-cholesterol diet, high-fat and cholesterol diet respectively, for a period of four weeks.
Results: After an induction phase, a stable model of renal injury was established with the aspects of early T1DM
kidney disease, These aspects were severe hypertriglyceridemia, hypercholesterolemia, proteinuria with mesangial
matrix accumulation, upgraded creatinine clearance, significant cholesterol and triglyceride deposition, and
increasing glomerular surface area, thickness of basement membrane and mesangial expansion. The mRNA levels
of sterol regulatory element binding protein-1c, transforming growth factors-β, plasminogen activator inhibitor-1,
tumor necrosis factor-α and interleukin-6 in the D-HFHC group were significantly up-regulated compared with
control groups.
Conclusions: This study presents a novel, non-transgenic, non-surgical method for induction of renal injury in
hamsters, which is an important complement to existing diabetic models for pathophysiological studies in early
acute and chronic kidney disease, especially hyperlipidemia. These data suggest that both severe hypertriglyceridemia
and hypercholesterolemia can accelerate renal injury in the early development of T1DM.
Keywords: High-fat, High-cholesterol, Streptozotoncin, Hyperlipidemia, Hypertriglyceridemia, Hypercholesterolemia,
Diabetes, Hamsters, Renal injury* Correspondence: microvet@163.com
3State Key Laboratory Breeding Base for Zhejiang Sustainable Plant Pest
Control, Agricultural Ministry Key Laboratory for Pesticide Residue Detection,
310021 Hangzhou, Zhejiang, China
4Institute of Quality and Standard for Agro-products, Zhejiang Academy of
Agricultural Sciences, 310021 Hangzhou, Zhejiang, China
Full list of author information is available at the end of the article
© 2015 He et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
He et al. BMC Nephrology  (2015) 16:51 Page 2 of 12Background
Hyperlipidemia is a metabolic syndrome characterized
by diverse lipid profiles (e.g. hypertriglyceridemia, hyper-
cholesterolemia, and familial combined hyperlipidemia)
[1], and is emerging as an independent risk factor for
progression of renal disease in diabetes [2,3]. Findings
from basic and clinical studies strongly suggest that
hyperlipidemia can lead to glomerulosclerosis and tubu-
lointerstitial fibrosis and induce renal injury by promot-
ing the intrarenal generation of reactive oxygen species,
glomerular infiltration of monocytes and macrophages,
and podocyte damage [4]. However, these findings were
obtained at stages with extensive renal injury and may
have represented secondary effects.
Diabetes has been described as a major global health
problem and rapidly growing cause of death and disabil-
ity [5]. At least 50%, and up to as high as 90% of patients
with type 1 diabetes mellitus (T1DM) and type 2 dia-
betes mellitus (T2DM) develop kidney disease, tradition-
ally termed diabetic nephropathy, the disease burden
being greater with T1DM [6-8]. Lipid profiles are com-
monly abnormal in the early stages of T2DM, observed
as a temporal pattern that correlates with the presence
of diabetic nephropathy [9]. Accumulating data from
several large scale trials of patients with T2DM also
point to early lipid abnormality as a major independent
risk factor for the development of diabetic nephropathy
[10], but the early effects of triglyceride and cholesterol
abnormalities on renal injure in T1DM are not fully
understood and the mechanisms underlying this need
further exploration. One of the reasons is the lack of re-
liable animal models mimicking severe hypertriglyc-
eridemia and hypercholesterolemia of human T1DM to
assist in the understanding of the earlier incidence of
diabetic nephropathy.
There have previously been some studies on investiga-
tion models of T1DM with exacerbation of diabetic kid-
ney disease, such as renin overexpression, knockout of
the bradykinin B2 receptor, and decorin deficiency
[11-13]. The patterns of disease initiation and develop-
ment in most of these studies do not appear to be analo-
gous to the clinical situation in humans. Besides these
transgenic animals, the widespread established tech-
niques for induction of renal injury in mice are mostly
dependent on surgical interventions, which lead to inter-
stitial fibrosis by infiltration of macrophages and tubular
cell death by apoptosis and necrosis, and 5/6 nephrec-
tomy [14]. There are also several limitations, including
a substantial mortality rate when not performed ad-
equately, non-reversible, and phenotypic alterations re-
lated to the surgical procedure rather than impaired
kidney function [15]. In attempts to circumvent these
obstacles, several studies have reported that rodent
models (mice and rats) fed a high fat or high cholesteroldiet have been used to investigate the nephropathy asso-
ciated with hyperlipidemia [16,17]. Mice and rats are not
better than hamsters for reproducing hyperlipidemia.
This is because hamsters have a unique and distinct hep-
atic lipid metabolism with a greater plasma lipid concen-
tration than rats, and have cholesteryl ester transfer
protein activities in plasma, which are very similar to
that of humans [18,19]. Similarities between hamsters
and humans are also obtained on the effects of dietary
cholesterol on plasma lipid profiles [20].
Based on the available evidence, there are few studies
that have specifically investigated the effects of severe
hypertriglyceridemia and hypercholesterolemia on renal
tissues in the early development of T1DM. The effects
and mechanism of hyperlipidemia on renal injury re-
quire further investigation. Therefore, the objectives of
the present study were to establish a novel, non-
transgenic, and non-surgical animal model induced by a
short-term high-fat/high-cholesterol diet and low-dose
streptozotocin(STZ) treatment in Golden Syrian ham-
sters, and to explore the mechanisms underlying severe
hypertriglyceridemia and hypercholesterolemia produ-
cing accelerated renal injury in this model.
Methods
Ethics statement
All animal procedures were approved by the Institutional
Committee on the Use of Live Animals in Teaching and
Research at Zhejiang Academy of Agricultural Sciences.
‘Principles of Laboratory Animal Care’ (NIH Publication
No.85-23, revised 1996) were followed (Additional file 1).
Chemicals and reagents
STZ, pioglitazone and glipizide were purchased from
Sigma-Aldrich Chemical Co. (Skbio Life Sciences Tech-
nology, Beijing, China). Rat insulin ELISA kitS were
purchased from Westang Biotechnology Co. (Shanghai,
China). Glucose assay kits, cholesterol assay Kits, and
triglyceride assay Kits were produced from BioSino
Bio-technology and Science Co.(Beijing, China). Commer-
cial fed a standard rodent chow (4% fat, 24% protein and
4.5% crude fiber), high-fat (15% fat) diet, high -cholesterol
(0.5% cholesterol) diet, and high-fat and high-cholesterol
(15% fat and 0.5% cholesterol) diet were purchased from
Institute of Laboratory Animal Sciences , Chinese Acad-
emy of Medical Sciences. BCA protein assay kits were pur-
chased from Bio-Rad Company (Bio-Rad Biotechnology,
Beijing, China).
Hamsters
Male Golden Syrian hamsters were purchased from
Beijing Vital River Laboratory Animal Technology
Co.,Ltd and bred at the Zhejiang Academy of Agricul-
tural Sciences Laboratory Animal Centre. Hamsters aged










TNF-α: tumor necrosis factor-α; SREBP-1c: sterol regulatory element binding
protein-1c; PAI-1: plasminogen activator inhibitor-1; IL-6: interleukin-6; TGF-β:
transforming growth factors-β; VEGF: vascular endothelial growth factor.
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experiments. All animals had free access to commer-
cially available standard rodent chow and water. Ani-
mals were singly housed in plastic cages(370 × 215 ×
170 mm) under controlled atmosphere (23 ± 1°C, 45 ±
5% relative humidity), fresh air exchange and 12/12 h
light/dark cycle.
Determination of threshold dose of STZ on hamsters
producing insulin deficient
Twenty-four hamsters were rendered diabetes by intraper-
itoneal injections of STZ on 3 consecutive days, at dose of
either 20 mg/kg, 30 mg/kg, 40 mg/kg or 50 mg/kg once
daily in 0.05 M citrate buffer (pH 4.5). The control group
was given 0.05 M citrate buffer (pH 4.5) without STZ. All
groups (n = 6 in each group) were fed a standard rodent
chow for 10 days after injection. Blood samples were col-
lected to determine the effects of different doses of STZ
on plasma glucose (Glu) and body weight.
Model of hamsters induced by STZ
Ten days after intraperitoneal STZ injections, hamsters
with a plasma Glu concentration more than 12 mmol/L
were selected as insulin deficient ones for subsequent
experiments [21]. Twenty-four STZ-treated hamsters
were randomly divided into four groups (n = 6 in each
group) according to the type of diet they recceived: ei-
ther standard rodent chow (D-C), high-fat diet (D-HF),
high-cholesterol diet (D-HC) or high-fat and high-
cholesterol diet (D-HFHC). Twenty-four control hamsters
were also divided into four groups (n = 6 in each group)
according to the different diets they received(C-C, C-HF,
C-HC or C-HFHC). All groups were fed for 4 weeks.
Twenty-four hours urine samples were collected using
metabolic cages before hamsters were anesthetized with
pentobarbital sodium and exsanguinated by cutting the
abdominal aorta.
Determination of high-fat/high-cholesterol feeding and
STZ-treated type1 diabetic hamsters through anti-diabetic
compound effects
To determine the type of diabetes in high-fat/high-
cholesterol fed and STZ-treated hamsters, classes of
anti-diabetic drugs, insulin sensitizer (pioglitazone) and
insulin secretagogue (glipizide), were used to treat on
this model. Ten days after STZ administration was
followed by 4 weeks of dietary manipulation, high-fat/
high-cholesterol and STZ-treated hamsters were ran-
domly divided in three groups of six hamsters per group
(Glu >12 mmol/L). Diabetic hamsters were orally treated
with pioglitazone (10 mg/kg once daily for 7 days) and a
single dose of glipizide (5 mg/kg). The control group
was orally given vehicle 1% Na-CMC (2 ml/kg). Blood
samples were collected at 3 h after administration of thevehicle or test compounds to determine the effects of
the drugs on plasma biochemical parameters: plasma
Glu, total cholesterol (TC) and triglyceride (TG) levels
in the treated animals.
Measurement of plasma biochemical parameters
Blood samples were taken from the venous retroorbital
plexus o hamsters after an overnight fast under pentobar-
bital sodium anesthesia (50 mg/kg). Plasma Glu, TC and
TG levels were determined using enzymatic methods. In-
sulin was assayed with a rat insulin ELISA kit. Plasma and
urinary creatinine concentrations were measured by an
automated technique using the Jaffe method. Creatinine
clearance is expressed in milliliters per minute.
Measurement of urinary protein excretion
Twenty four hours urine samples were collected indi-
vidually using metabolic cages. Urine was centrifuged at
3000 × g for 10 min, and the supernatant was collected.
Urinary protein content was measured using protein
assay kits. All samples were assayed in triplicate and
mean values were used.
Renal histological analysis
The left kidney was embedded in paraffin and cut into
3 μm thick sections for staining with Periodic acid-Schiff
(PAS) and Masson’s trichrome. The kidney was also em-
bedded in OCT compound (Tissue-Tek; Sakura Finetek
USA) for cryostat sections, then Oil Red O staining was
performed. Quantitative morphometric analysis of glom-
eruli was performed as described previously [22]. One sec-
tion was used for measurement of glomerular area for
each hamster. Each kidney of each animal was trimmed
on the same place during the preparation of the slide. Fifty
different glomeruli from the cortical area of each kidney
were observed and images were taken using a digital
microscope (BH-2; Olympus, Tokyo, Japan). For every
investigated glomerulus, total glomerular area and glom-
erular tuft area were determined by tracing the outline of
Table 2 Plasma Glu levels after 10 days of STZ treatment
Group N Dose of STZ B.W Glu
(mg/kg) (g) (mmol/l)
STZ-20 6 20 110 ± 6* 8.6 ± 3.2
STZ-30 6 30 108 ± 5* 16.2 ± 2.5**
STZ-40 6 40 106 ± 4* 16.9 ± 3.3***
STZ-50 6 50 102 ± 6** 17.2 ± 4.9***
Control 6 0 116 ± 4 7.2 ± 2.5
***P<0.001, **P<0.01, *P<0.05 vs control group.
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Image-Pro Plus 4.5 soft ware (Media Cybernetics, Silver
Spring, MD, USA). This analysis was conducted in a
double blind manner.
Lipid extraction, total RNA extraction and real-time PCR
At the end of the experiments, hamsters were killed and
kidneys were harvested. The right kidney was removed and
immediately placed in liquid nitrogen for total RNA extrac-
tion and renal lipid extraction. Total kidney lipid was
extracted using the method of Bligh et al. [23]. TC and
TG were measured as described above. Total RNA from
the kidney was extracted using TRI Reagent (Molecular
Research Center, USA) and first-strand cDNA was gener-
ated using a reverse transcription kit (Invitrogen, USA). In
25 μl reverse transcription reaction system, 5 μg of total
RNA was used for each sample. Quantitative real-time PCR
was performed in 35 cycles using an opticon continuous
fluorescence detection system (MJ Research, Waltham,
MA) with SYBR green fluorescence (Molecular Probes,
Eugene, USA). All samples were quantitated using the com-
parative CT method for relative quantitation of gene
expression, normalized to β-actin and 18S [24,25]. The
primers used are listed in Table 1. The following primer
pairs were designed using an online version of primer 3
software (http://bioinfo.ut.ee/primer3/) through analysis ofTable 3 Glu, TG and TC levels for each group 4 weeks after a
Group N B.W Glu
(g) (mmol/l)
C-Ca 6 111 ± 7 7.2 ± 1.3
C-HFa 6 141 ± 4 8.0 ± 1.5
C-HCa 6 115 ± 4 6.4 ± 0.6
C-HFHCa 6 139 ± 4 9.0 ± 0.9
D-Cb 6 98 ± 16* 20.1 ± 5.8***
D-HFb 6 97 ± 11*** 21.7 ± 6.5***
D-HCb 6 94 ± 1** 19.6 ± 1.7***
D-HFHCb 6 100 ± 8*** 16.3 ± 3.9***
a non-diabetic hamsters; b diabetic hamsters.
***P<0.001, **P<0.01, *P<0.05 vs non-diabetic counterparts(C-C,C-HF,C-HC and C-HFH
### P<0.001, ## P<0.01, # P<0.05 vs D-C group.available golden hamster genome sequences from NCBI.
The quantitative real-time PCR was done in triplicates. The
PCR conditions were as follows: incubate at 94°C for 5 mi-
nutes 5; 35 cycles of 94°C for 30 seconds, 55°C for 30 sec-
onds, and 72°C for 30 seconds; incubate at 72°C for
7 minutes; perform melting curve from 65°C to 95°C: read
every 0.2°C; hold for 3 sec between reads; incubate at 4°C
for 30 min.
Statistics analysis
All results are expressed as means ± SD. Statistical com-
parison between groups were performed using 2-way
ANOVA followed by a Fisher test. A P value ≤ 0.05 was
considered statistically significant.
Results
Determination of threshold dose of STZ on hamsters
producing insulin deficient
Intraperitoneal injection of STZ (30 mg/kg, 40 mg/kg
and 50 mg/kg) on 3 consecutive days caused hypergly-
cemia (fasting blood glucose ≥ 12 mmol/L) in all
hamsters. The 20 mg/kg dose of STZ did not produce
significant hyperglycemia (Table 2). All STZ-treated
hamsters exhibited a slight reduction in body weight,
and some died within 10 days of STZ (40 mg/kg and
50 mg/kg) administration (data not shown). High-fat
and/or high-cholesterol diet in combination with a low
dose of STZ (30 mg/kg) was chosen for the generation
of severe hypertriglyceridema and hypercholesterolemia
in T1DM models for subsequent studies.
Plasma biochemical analysis
In response to STZ-induced (30 mg/kg) diabetes, all
groups of diabetic hamsters had a modest reduction in
plasma insulin levels and exhibited hyperglycemia (fast-
ing blood glucose ≥12 mmol/L). Body weights of the
four diabetic groups (D-C, D-HF, D-HC, and D-HFHC)high fat and /or high cholesterol diet
TG TC Insulin
(mmol/l) (mmol/l) (ng/ml)
1.4 ± 0.7 4.3 ± 0.6 1.58 ± 0.17
1.6 ± 0.6 3.8 ± 0.5 1.55 ± 0.12
1.6 ± 0.6 7.1 ± 0.6** 1.56 ± 0.05
7.8 ± 3.3** 26.6 ± 11.4** 1.59 ± 0.07
1.8 ± 0.7 4.3 ± 1.1 1.12 ± 0.05**
6.1 ± 3.1**## 8.3 ± 4.5*# 1.18 ± 0.14**
3.8 ± 1.1**## 30.8 ± 9.5**## 1.18 ± 0.06***
116.7 ± 69.2***### 75.8 ± 49.5***### 1.17 ± 0.07***
C).
Figure 1 Appearance of plasma after 4 weeks STZ-treatment in combination with a chow diet or high-fat/high-cholesterol diet. C-C(A),D-C(B),C-
HFHC(C) and D-HFHC(D).
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control groups (C-C, C-HF, C-HC, and C-HFHC). In
non-diabetic hamsters fed a high-fat and/or high
-cholesterol diet for 4 weeks, plasma TG and TC levels
increased slightly (Table 3). In the diabetic groups,
plasma TG and TC levels increased modestly in ham-
sters fed a high-fat or high-cholesterol diet. Hamsters in
the D-HFHC group developed severe hypertriglyc-
eridemia and hypercholesterolemia, the plasma sample
of this group showed a milky appearance (Figure 1), in
which plasma TG and TC levels reached 110 mmol/L
and 75 mmol/L, respectively (Table 3).
Determination of high-fat/high-cholesterol feeding and
STZ-treated T1DM hamsters through anti-diabetic
compound effects
Both antihyperglycemic compounds (pioglitazone and glipi-
zide) were not validated for the high-fat/high-cholesterol fedFigure 2 Effect of anti-diabetic compounds on various biochemical
parameters in high fat/high cholesterol and STZ-treated hamsters. Values
are mean ± SD (n = 6).
Figure 3 Kidney weight to body weight ratio (A), urinary protein
excretion (B), and creatinine clearance (C) of hamsters from each
group. n = 6 in each group. ***P< 0.001, **P< 0.01, *P< 0.05,diabetic
vs non-diabetic counterparts; ### P< 0.001, ## P< 0.01, # P< 0.05 ,
diabetic with different diets vs D-C group.
Figure 4 Oil Red O staining from hamsters in each group 4 weeks after a high fat and /or high cholesterol diet(magnification × 200).
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diabetic hamster model. Oral administration of pioglitazone
for 7 days did not significantly reduce plasma Glu, TG, TC
and insulin levels. When compared with vehicle-treated dia-
betic hamsters (Figure 2). Likewise, oral administration of
glipizide (5 mg/kg) also failed to elicit any significant effect
on these biochemical parameters (Figure 2).Kidney functions
All diabetic groups fed with a high-fat and/or high choles-
terol diet had renal hypertrophy (Figure 3) and urorrhagia
(data not shown) compared with non-diabetic groups.
Urinary protein excretion increased significantly in the
D-HFHC group compared with the other diabetic groups
(P<0.01) (Figure 3). Creatinine clearance increased in the
D-HFHC group only (Figure 3).Figure 5 Renal triglyceride and cholesterol concentrations of each
group from hamsters in each group.Renal lipid deposition
Renal Oil Red O staining was performed to determine
neutral lipid accumulation. The D-HFHC group and
D-HC group showed an increased Oil Red O accumula-
tion in glomeruli (Figure 4). There was a significant
increase of TG and TC content in kidneys from the
D-HFHC group (Figure 5).Histopathological examination of kidneys
Representative kidney sections stained with PAS (Figure 6)
and Masson’s trichrome (Figure 7) are shown. No major
glomerular pathology changes were observed in any non-
diabetic group. In contrast, diabetic hamsters showed
significant vacuolar degeneration of glomeruli. With PAS
staining, it was observed that diabetic hamsters manifested
a slight increase in glomerular surface area compared
with corresponding controls. There were significant in-
creases of glomerular surface area (Figure 8), thickness
Figure 6 PAS staining of kidney cortex from hamsters in each group 4 weeks after a high fat and /or high cholesterol diet(magnification × 400).
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D-HFHC group (Figure 6) compared with the D-C group.
An appreciable accumulation of collagen in glomeruli was
also seen in D-HFHC hamsters (Figure 7). The D-HF and
D-HC groups did not exhibit mesangial expansion and
glomerular collagen deposition (Figures 6, and 7).Figure 7 Masson’s trichrome staining of kidney cortex from hamsters in ea
diet(magnification × 400).Renal gene expression
In diabetic groups, renal plasminogen activator inhibitor
(PAI-1) and tumor necrosis factor-alpha (TNF-α) mRNA
expression were significantly up-regulated compared
with non-diabetic groups. Expression of these genes in-
creased significantly in the D-HFHC group comparedch group 4 weeks after a high fat and /or high cholesterol
Figure 8 Glomerular areas of hamsters in each groups. n = 6 in
each group. ***P<0.001, **P< 0.01, *P< 0.05, diabetic vs non-diabetic
counterparts; ### P< 0.001, ## P< 0.01, # P< 0.05 for diabetic with
different diets vs D-C group.
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of sterol regulatory element binding protein-1c (SREBP-
1c) had a fold increase in the D-HFHC group compared
with the D-C group (Figure 9). D-HFHC hamsters
showed an increase in abundance of renal mRNA of
transforming growth factor-beta (TGF-β) and interleukin
6 (IL-6). Diabetic hamsters fed other diets did not show
any change (Figure 9). Renal vascular endothelial growth
factor (VEGF) mRNA expression did not change in any
group (Figure 9).
Discussion
To the best of the authors’ knowledge, this is the first
study to report an animal model with severe hypertriglyc-
eridemia and hypercholesterolemia in non-transgenic and
non-surgical T1DM animals. The model was achieved in
hamsters induced with short-term high-fat/high choles-
terol diets and low dose STZ-treated. The results sug-
gested that T1DM model hamsters developed severe
hypertriglyceridemia, hypercholesterolemia, proteinuria
with mesangial matrix accumulation and produced accel-
erated renal injury in 4 weeks. Postprandial plasma TG
levels increased 110 mmol/L in the HFHC group , which
was five times the previous value reported in which ham-
sters were fed a saturated fat, non purified diet (10 g but-
ter/100 g diet, 0.1 g cholesterol/100 g) [26]. One rat model
was previously established after 15 weeks that showed
microalbuminuria, an increased creatinine clearance rate
and mesangial expansion using a combination of a high-
fat diet, low dose STZ treatment and heminephrectomy
[27]. Another hamster model was induced to moderate
diabetes and severe glomerulosclerosis with a saturated-
fat diet in an experiment lasting 20 weeks [28]. Comparing
to these previous reports, the current study suggested that
this diabetic hamsters model was a more cost effective,easier to develop and most suited for pathophysiology
studies on renal injuries at the early stage of T1DM.
Both insulinotropic (glipizide) and insulin-sensitizing (pi-
oglitazone) agents failed to reduce plasma Glu, TG, TC
and insulin levels, when compared with vehicle-treated dia-
betic hamsters. This indicated that hamsters fed high-fat/
high cholesterol diets, and a low dose of STZ (30 mg/kg)
resembled T1DM. Previous studies have mainly focused
on the effects of dyslipidemia in the development and
progression of renal disease in T2DM [27,29-31]. How-
ever, clinical studies demonstrated that dyslipidemia is
mandatory in patients with T1DM [32,33]. Thus, our initial
attempts were directed towards finding the threshold dose
of STZ that was low enough to guarantee the development
of T1DM in high-fat/high cholesterol hamsters with circu-
lating insulin deficiency. In this study, low dose of STZ
(30 mg/kg) succeeded in producing hyperglycemia in
T1DM hamsters due to the direct pancreatic beta cell de-
struction and the resulting insulin deficiency, while T2DM
rats induced by low dose of STZ (40 mg/kg) was primarily
the consequence of insulin resistance [27]. These distinct
differences between hamsters and rats meant that the ham-
sters might well be mimicking biochemical and physical
characteristics of people with diabetes.
In the current study, it was observed that the
D-HFHC group developed severe hypertriglyceridemia
and hypercholesterolemia with significantly increasing
in plasma TC and TG, which was consistent with previ-
ous reports [18,34]. The severe hypertriglyceridemia ob-
served in the hamsters may be due to increased
absorption and formation of triglycerides in the form
of chylomicrons following exogenous consumption of
a diet rich in fat, or through increased endogenous
production of TG-enriched hepatic very low density
lipoprotein and decreased TG uptake in peripheral tis-
sues [35]. Hypercholesterolemia may be attributed to
increased dietary cholesterol absorption from the small
intestine following the intake of fat in a diabetic condi-
tion [36]. One striking finding of the current experi-
ments was the synergistic effects of dietary fat and
cholesterol on plasma TG and TC levels in T1DM de-
veloping severe hypertriglyceridema and hypercholes-
terolemia. The results indicated that plasma TC could
be notably elevated by dietary cholesterol combined
with saturated fat and total fat in the diet. A previous
study reported that dietary hypercholesterolemia had
little effect on plasma TC in rats [37]. The current study
suggested that combined dietary fat and cholesterol not-
ably improved plasma TC levels in T1DM hamsters
more than either fat or cholesterol alone, which was in
agreement with STZ-induced (insulin-deficient) dia-
betes in rats enhancing fat and cholesterol absorption
and reducing cholesterol synthesis [38]. This animals
model also showed insulin deficiency, as determined by
Figure 9 Effects of STZ-induced diabetes on glomerular gene expression. *** P<0.001, **P< 0.01, *P< 0.05 diabetic vs non-diabetic counterparts;
### P<0.001, ## P<0.01, # P<0.05, diabetic with different diets vs D-C group.
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previously reported saturated-fat diet hamster model
with insulin resistance [28]. The current study sug-
gested that low doses of STZ could induce T1DM in
hamsters by recruiting immune cells for immune-
mediated apoptotic cell death. Hence, this model withthe involvement of both insulin deficiency and obvious
body weight loss in the development of diabetes could
be suitable for studying the pathophysiology of T1DM.
Logan et al. examined the effects of a high-fat diet on
renal function in STZ-treated rats and observed that
there was no difference in urinary protein excretion
He et al. BMC Nephrology  (2015) 16:51 Page 10 of 12between diabetic and control rats [39]. Cooper et al.
added cholesterol to the diet of both STZ-injected
(55 mg/kg) and normal rats and observed that 32 weeks
on a high cholesterol diet did not change urinary albu-
min levels in normal or diabetic rats [40]. Being incon-
sistent with these findings, the results of this study
showed that urinary protein excretion increased signifi-
cantly in hamsters fed a high-fat/high-cholesterol diet.
The detrimental effects of a high-fat diet on renal func-
tion might be triggered by a high-cholesterol diet. Cre-
atinine clearance has been used for many decades to
estimate glomerular filtration rate, and is often used
for the initial evaluation of renal diseases, such as glom-
erulonephritis [41]. In the current study, creatinine
clearance was significantly elevated in high fat/high chol-
esterol diabetic hamsters induced by STZ which was also
an indication of renal dysfunction. Given that renal lipid
deposition and renal histopathological lesions were ob-
served in high-fat/high-cholesterol diabetic hamsters, a
high-fat/high-cholesterol diet was considerably effective
at inducing structural and functional abnormalities in
the diabetic kidney. The results also suggested that ham-
sters fed a high fat diet for a short period of time fail to
produce an evident renal injury, while diabetic hamsters
fed with high-fat/high-cholesterol diet exhibited obviously
histopathological changes even after 4 weeks of dietary
manipulation. Glomerulosclerosis was also seen in this
group in long term treatment (up to 2 months). Therefore,
the synergistic effects of hypertriglyceridemia and hyper-
cholesterolemia led to produce accelerated renal injury in
T1DM hamsters in a short period of time.
Though it is known that dysregulation of renal lipid
metabolism plays an important role in the pathogenesis
of diabetic nephropathy, the underlying lipids mecha-
nisms mediating glomerulosclerosis have not been fully
elucidated. One possible explanation is that lipid can
stimulate mesangial cells to proliferate, produce excess
basement membrane material and result in the develop-
ment of sclerotic glomerular lesions [42]. Lipid extrac-
tion analysis showed lipid deposition in the kidney of
the D-HFHC group, and was further confirmed by Oil
Red O staining. This result could possibly be explained
by up-regulation in renal gene expression of SREBP-1c.
SREBP-1c is known to be a key transcription factor
for the regulation of lipogenic gene expression and in-
crease of triglyceride storage in the liver [43,44]. In the
current study, renal expression of SREBP-1c mRNA
showed a one fold increase in hamsters in the D-HFHC
group, which possibly resulted in lipid accumulation in
the kidney by TGF-β inhibiting glomerular endothelial,
epithelial, and mesangial proliferation and mediating
the hypertrophic and fibrotic/sclerotic manifestations of
diabetic nephropathy. Our results also showed that in-
creased expression of TGF-β, PAI-1, and pro-inflammatorycytokines(TNF-α and IL-6) were found in the D-HFHC
group, which was in alignment with a previous report [43].
Proteinuria is considered the earliest clinical indicator of in-
cipient diabetic nephropathy, and podocyte-derived VEGF
is involved in the proteinuria of diabetes [45]. Increased ex-
pression of VEGF in the glomerular, and tubulointerstitium
were reported in STZ induced mice and rat models of
diabetic nephropathy, as well as experimental models of
T2DM [46,47]. However, in the current study, renal VEGF
expression in hamsters in the D-HFHC group did not in-
crease, and even showed a tendency to decrease, which was
similar to human diabetic nephropathy. Lindenmeyer et al.
found a significant decrease in VEGF expression on mRNA
and protein levels in human diabetic nephropathy, and sug-
gested that a lack of VEGF, rather than an excess of VEGF,
might contribute to the progressive disease in human dia-
betic nephropathy [48]. The results of the current study
indicateed that a lack of VEGF in this model might also in-
duce renal injury in type 1 diabetic hamsters.
Conclusions
In conclusion, the results indicated that severe hypertri-
glyceridemia and hypercholesterolemia produced accel-
erated renal injury in hamsters during the early
development of T1DM induced by short-term high-fat/
high-cholesterol diet and low dose STZ treatment. TG
and TC deposition, glomerulosclerosis, mesangial hyper-
plasia, and proteinuria might combine to cause renal in-
jury in T1DM hamsters in a short period of time. The
underlying molecular mechanism might be increased
expression of SREBP-1c associated with TGF-β, TNF-α,
IL-6 and PAI-1. Furthermore, this study provides a dia-
betic animal model that is more cost effective, easier to
develop and most suited for researching the pathogenesis
and treatment of diabetes and associated dyslipidemia.
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